Proteomic analysis of serum for identification of potential biomarkers predicting response of patients with refractory multiple myeloma to bortezomib‑based therapy

Pol Arch Intern Med. 2017 Jun 30;127(6):386-387. doi: 10.20452/pamw.4057. Epub 2017 Jun 30.
No abstract available

Publication types

  • Editorial
  • Comment

MeSH terms

  • Biomarkers
  • Bortezomib*
  • Gene Expression Profiling
  • Humans
  • Multiple Myeloma*
  • Proteomics

Substances

  • Biomarkers
  • Bortezomib